ArticleInfluenza and other respiratory viruses2025
Prevalence and Age at Diagnosis of Risk Factors for Severe Respiratory Syncytial Virus Disease Among US Adults: An Analysis of 2011-2020 NHANES Data.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Clinical and Symptomatic Burden Among Older Adults with Respiratory Syncytial Virus: A Real-World Survey in Five European Countries.Infectious diseases and therapy · 2026Article
- Prevalence and Age at Diagnosis of Risk Factors for Severe Respiratory Syncytial Virus Disease Among US Adults: An Analysis of 2011-2020 NHANES Data.Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) vaccines are approved in the United States (US) among adults ≥ 60 years of age (YoA). Understanding disparities in risk factors (RFs) for severe RSV disease by social determinants of health is crucial for equitable RSV vaccination among at-risk adults. We investigated diagnosed/undiagnosed RF prevalence, age at RF diagnosis/identification, and association of key characteristics with RF diagnosis/identification among US adults.
methodsWe analyzed 2011-2020 National Health and Nutrition Examination Survey (NHANES) data to calculate RF prevalence and mean age at RF diagnosis/identification. Multivariable regression models were developed to estimate associations between characteristics and RF diagnosis/identification. Results were weighted to reflect the US noninstitutionalized adult population ≥ 20 YoA.
resultsAfter weighting, the analysis included a sample of 233,118,491 adults. Overall, 28.0% had ≥ 1 diagnosed RF (12.8% pulmonary; 9.2% cardiovascular; 14.1% endocrine/metabolic). Undiagnosed diabetes and renal disease were identified in 3.7% and 12.5% of adults, respectively. Among those with ≥ 1 diagnosed RF, mean age at RF diagnosis was 40.1 years and 60.0% were diagnosed before 50 YoA. Increasing age, belonging to a racial or ethnic minority group, and lower income were significantly associated with having ≥ 1 RF.
conclusionsApproximately one in four adults had ≥ 1 diagnosed RF for RSV, with most diagnosed before 50 YoA. Adults in racial and ethnic minority and socioeconomically disadvantaged groups were more likely to have RFs and be diagnosed at younger ages. Efforts are needed to ensure all US adults at increased risk for severe RSV disease have access to RSV vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.